Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 32 of 45

Summary of Benefits: DMARD Combinations Versus Monotherapies (1 of 2)

In patients with rheumatoid arthritis who had inadequate disease control and required a change in treatment, combination therapy with a biologic disease-modifying anti-rheumatic drug (DMARD) and methotrexate (MTX) achieved greater improvements in some outcomes than either a biologic DMARD or MTX alone.

Combination therapy achieves greater improvement than biologics alone in disease activity and radiographic progression (Strength of Evidence = Moderate).

Combination therapy achieves greater improvement than MTX alone in clinical response and functional capacity (Strength of Evidence = High) as well as in quality of life (Strength of Evidence = Moderate).